The PROMISE Pediatric Study 6 to 11 Years Old

  • STATUS
    Recruiting
  • End date
    Jul 1, 2023
  • participants needed
    180
  • sponsor
    David Nichols, MD
Updated on 25 July 2021
Investigator
Laurel Couture
Primary Contact
Ann & Robert H. Lurie Children's Hospital of Chicago (8.9 mi away) Contact
+19 other location
fibrosis
ivacaftor
tezacaftor
elexacaftor

Summary

This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in children (6-11 years of old) with one or more copies of the F508del mutation, study the effects of ETI across a number of CF disease manifestations, and collect specimens for future research. Subjects in the study will have one "before ETI" visit within 30 days before initiation of the therapy and five "after ETI" visits over a 24-month follow-up period. The duration of participation for each subject is 25 months. NOTE: Study will not begin unless and until FDA approval for ETI in the 6-11 age group is granted.

Description

While nearly 2000 mutations have been described, the most common disease causing CFTR mutation is F508del, which is found in >85% of patients followed in the US CF Patient Registry. Two CFTR corrector drugs (elexacaftor and tezacaftor) plus the potentiator ivacaftor have been developed and approved as a triple combination therapy for CF patients (12 years old and above) with one or two copies of the F508del mutation. We predict that over 90% of pediatric CF patients (age 6-11 y/o) will be eligible for highly effective CFTR modulator therapy in the U.S.

The PROMISE Pediatric Study is designed to measure the direct and indirect CFTR dependent anion secretion by collecting and analyzing clinical research outcomes and biomarkers on pediatric patients both before and after they begin treatment with ETI. This study will investigate the impact of ETI across a wide range of CF disease manifestations and organ systems. While specific biomarkers of special interest have been selected for detailed analysis in this study, an additional important goal is to collect blood, urine, stool, and airway epithelial cell specimens for long-term storage in a biorepository to enable future research. These samples can be made available for research beyond the current scope of work. The PROMISE Pediatric Study will provide a coordinated collection of clinical research outcomes data that can be linked with these specimens.

Details
Condition Pulmonary Disease, Cystic Fibrosis, Pancreatic disorder, Cystic Fibrosis in Children
Clinical Study IdentifierNCT04613128
SponsorDavid Nichols, MD
Last Modified on25 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Written parental informed consent and assent obtained from subject and the subject's legal guardian
Be willing and able to adhere to the study visit schedule and other protocol requirements
All genders 6-11 years old on Day 1
Diagnosis of CF
CFTR mutations consistent with the FDA labeled indication for the ETI
Physician intent to prescribe the ETI
Able to attempt the testing and procedures required for this study, as judged by the investigator
Enrolled in the Cystic Fibrosis Foundation Patient Registry
Clinically stable with no significant changes in health status within the 14 days prior to Visit 1 (and inclusive of Visit 1)

Exclusion Criteria

Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Use of any ETI within the 180 days prior to Visit 1
Any acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids within the 14 days prior to Visit 1 (inclusive of Visit 1) for lower respiratory tract symptoms
Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme, hypertonic saline, azithromycin, inhaled tobramycin, Cayston, Kalydeco, Orkambi, Symdeko) within the 4 weeks prior to Visit 1 (inclusive of Visit 1)
Use of an investigational agent within the 28 days prior to Visit 1
Use of chronic oral corticosteroids (equivalent to 10 mg. or more per day of prednisone) within the 28 days prior to Visit 1
Treatment for nontuberculous mycobacterial (NTM) infection, consisting of two antibiotics (oral, IV, and/or inhaled) within the 28 days prior to Visit 1
History of lung or liver transplantation,or listing for organ transplantation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note